ImmunityBio (NASDAQ:IBRX - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect ImmunityBio to post earnings of ($0.12) per share and revenue of $17.50 million for the quarter.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.11. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. On average, analysts expect ImmunityBio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
ImmunityBio Stock Up 0.2 %
Shares of IBRX traded up $0.01 during mid-day trading on Tuesday, reaching $2.11. 3,359,133 shares of the company's stock were exchanged, compared to its average volume of 5,232,620. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -2.29 and a beta of 0.33. The company has a 50-day simple moving average of $2.76 and a two-hundred day simple moving average of $3.42. ImmunityBio has a 52-week low of $2.00 and a 52-week high of $9.48.
Analyst Upgrades and Downgrades
Several analysts have commented on IBRX shares. BTIG Research started coverage on ImmunityBio in a report on Friday, January 10th. They issued a "buy" rating and a $6.00 price target for the company. D. Boral Capital reiterated a "buy" rating and set a $30.00 price objective on shares of ImmunityBio in a research note on Wednesday, April 23rd. Finally, HC Wainwright reiterated a "buy" rating on shares of ImmunityBio in a research report on Monday. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $12.19.
Read Our Latest Research Report on IBRX
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
See Also
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
